Umi Hani' Vismayanti Lismana1, Afiono Agung Prasetyo2. 1. A-Infection Genomic Immunology Cancer (A-IGIC) Research Group, Sebelas Maret University , Jl. Ir. Sutami 36A, Surakarta, Indonesia . 2. A-Infection Genomic Immunology Cancer (A-IGIC) Research Group, Sebelas Maret University , Jl. Ir. Sutami 36A, Surakarta, Indonesia; Department of Microbiology Faculty of Medicine, Sebelas Maret University, Jl. Ir. Sutami 36A, Surakarta, Indonesia; Center of Biotechnology and Biodiversity Research and Development, Sebelas Maret University, Jl. Ir. Sutami 36A, Surakarta, Indonesia .
Abstract
INTRODUCTION: The SNP HLA-C-35 kb (rs9264942) may contribute to the host immune defense mechanism by affecting the cell surface expression pattern of HLA-C and antigen presentation to CD8+ cytotoxic cells. Thus, this SNP may contribute to intracellular multidrug-resistant (MDR)-tuberculosis (TB) infection. AIM: To examine the association between the SNP HLA-C-35 kb (rs9264942) and the clinical profile of MDR-TB infection. SETTINGS AND DESIGN: MDR-TB-positive patients were followed from May 2012 to December 2013 to observe the progression of MDR-TB infection. Non-TB individuals and non-MDR-TB individuals were also recruited as controls. MATERIALS AND METHODS: The patients' HLA-C-35 kb (rs9264942) status was determined by PCR. RESULTS: The C allele was slightly more frequent in the MDR-TB patients than in the non-MDR TB patients (OR= 1.28; 95% CI: 0.701 - 2.328). The C allele was found to be more frequent in the MDR-TB patients exhibiting pulmonary fibrosis (OR= 2.13; 95% CI: 0.606 - 7.480) or pulmonary infiltrates (OR= 3.17; 95% CI: 0.690 - 14.598) and among the MDR-TB patients who were classified as underweight (OR= 8.00; 95% CI: 1.261 - 50.770). The CC genotype was associated with the treatment after failure of category II group (OR= 4.17; 95% CI: 1.301 - 13.346). CONCLUSION: The C allele SNP HLA-C-35 kb (rs9264942) may contribute to the clinical profile in MDR-TB infection.
INTRODUCTION: The SNP HLA-C-35 kb (rs9264942) may contribute to the host immune defense mechanism by affecting the cell surface expression pattern of HLA-C and antigen presentation to CD8+ cytotoxic cells. Thus, this SNP may contribute to intracellular multidrug-resistant (MDR)-tuberculosis (TB) infection. AIM: To examine the association between the SNP HLA-C-35 kb (rs9264942) and the clinical profile of MDR-TB infection. SETTINGS AND DESIGN: MDR-TB-positive patients were followed from May 2012 to December 2013 to observe the progression of MDR-TB infection. Non-TB individuals and non-MDR-TB individuals were also recruited as controls. MATERIALS AND METHODS: The patients' HLA-C-35 kb (rs9264942) status was determined by PCR. RESULTS: The C allele was slightly more frequent in the MDR-TB patients than in the non-MDR TB patients (OR= 1.28; 95% CI: 0.701 - 2.328). The C allele was found to be more frequent in the MDR-TB patients exhibiting pulmonary fibrosis (OR= 2.13; 95% CI: 0.606 - 7.480) or pulmonary infiltrates (OR= 3.17; 95% CI: 0.690 - 14.598) and among the MDR-TB patients who were classified as underweight (OR= 8.00; 95% CI: 1.261 - 50.770). The CC genotype was associated with the treatment after failure of category II group (OR= 4.17; 95% CI: 1.301 - 13.346). CONCLUSION: The C allele SNP HLA-C-35 kb (rs9264942) may contribute to the clinical profile in MDR-TB infection.
Entities:
Keywords:
Human leukocyte antigen C; Major histocompatibility complex class I; Rs9264942
Authors: Marie-Eve Blais; Yonghong Zhang; Tim Rostron; Harry Griffin; Stephen Taylor; Keyi Xu; Huiping Yan; Hao Wu; Ian James; Mina John; Tao Dong; Sarah L Rowland-Jones Journal: J Immunol Date: 2012-04-02 Impact factor: 5.422
Authors: Piotr Kopiński; Barbara Balicka-Ślusarczyk; Andrzej Dyczek; Adam Szpechciński; Grzegorz Przybylski; Agnieszka Jarzemska; Tomasz Wandtke; Marek Jankowski; Teresa Iwaniec; Joanna Chorostowska-Wynimko Journal: Folia Histochem Cytobiol Date: 2011 Impact factor: 1.698
Authors: R O Pinheiro; E B de Oliveira; G Dos Santos; G M Sperandio da Silva; B J de Andrade Silva; R M B Teles; A Milagres; E N Sarno; M P Dalcolmo; E P Sampaio Journal: Clin Exp Immunol Date: 2013-02 Impact factor: 4.330
Authors: Jason R Andrews; N Sarita Shah; Darren Weissman; Anthony P Moll; Gerald Friedland; Neel R Gandhi Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240